To explore whether host MSLN expression affects overall metastatic tumor burden, MSLNWT and MSLNKO mice were injected i.p. with ID8-RFP murine ovarian cancer cells and tumor progression was monitored via longitudinal in vivo imaging beginning 4 weeks post-injection (Figure 5A). This evidence concerns the gene MSLN and ovarian cancer.